|
Basic Characteristics of Mutations
|
|
Mutation Site
|
E484K |
|
Mutation Site Sentence
|
While the former is mainly associated with specific single amino acid mutations at residues within the receptor-binding domain (e.g., E484K/Q, Q493R, and S494P), a few cases of immune evasion after CCP were associated with recurrent deletions within the N-terminal domain of the spike protein (e.g., DeltaHV69-70, DeltaLGVY141-144 and DeltaAL243-244). |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RBD |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
Y |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
35008446
|
|
Title
|
Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
|
|
Author
|
Focosi D,Maggi F,Franchini M,McConnell S,Casadevall A
|
|
Journal
|
International journal of molecular sciences
|
|
Journal Info
|
2021 Dec 21;23(1):29
|
|
Abstract
|
The accelerated SARS-CoV-2 evolution under selective pressure by massive deployment of neutralizing antibody-based therapeutics is a concern with potentially severe implications for public health. We review here reports of documented immune escape after treatment with monoclonal antibodies and COVID-19-convalescent plasma (CCP). While the former is mainly associated with specific single amino acid mutations at residues within the receptor-binding domain (e.g., E484K/Q, Q493R, and S494P), a few cases of immune evasion after CCP were associated with recurrent deletions within the N-terminal domain of the spike protein (e.g., DeltaHV69-70, DeltaLGVY141-144 and DeltaAL243-244). The continuous genomic monitoring of non-responders is needed to better understand immune escape frequencies and the fitness of emerging variants.
|
|
Sequence Data
|
-
|